Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

Pharmacokinetic Factors and Therapeutic Drug Monitoring of Sirolimus

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Clinical Application of Sirolimus in Renal Post-Transplant Patients

Use of sirolimus in solid organ transplantation

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Prospective Observational Study of Sirolimus As Primary Immunosuppression after Renal Transplantation

Population Pharmacokinetic Characteristics of Sirolimus in Healthy Chinese Subjects and Renal Transplant Patients

Efficacy and Safety of Sirolimus and Tacrolimus after Renal Transplantation: a Meta-Analysis

Progress in the Application of Immunosuppressants to Renal Transplant

Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection

[Early Conversion from Calcineurin Inhibitor to Sirolimusto after Renal Transplantation:A Prospective, Open-Label and Non-Randomized Control Study].

Advances of sirolimus after conreal transplantation

The population pharmacokinetics of sirolimus and CYP 3 A 5 * 3 polymorphism in Chinese renal transplant patients

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Polymorphisms in Thecyp3a5gene Significantly Affect the Pharmacokinetics of Sirolimus after Kidney Transplantation

Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients

Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs

Study of immunoregulatory effect of sirolimus on xenotransplantaion with arterial patch

A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation

[Clinical Analysis of Sirolimus As an Alternative GVHD Prophylaxis for Patients with Kidney Injury Undergoing Allo-Hsct].

Population Pharmacokinetics of Sirolimus in Chinese Renal Transplantation Patients